CERTOLIZUMAB PEGOL

Open Access
Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol
Megan E.B. Clowse, Douglas C. Wolf, Frauke Förger, John J. Cush, Amanda Golembesky, Laura Shaughnessy, Dirk De Cuyper and Uma Mahadevan

The Journal of Rheumatology December 1 2015, 42 (12) 2270-2278; DOI: https://doi.org/10.3899/jrheum.140189
You have access
New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol
Alberto Cauli, Matteo Piga, Ennio Lubrano, Antonio Marchesoni, Alberto Floris and Alessandro Mathieu

The Journal of Rheumatology Supplement November 1 2015, 93 70-72; DOI: https://doi.org/10.3899/jrheum.150641
You have access
Tuberculosis Risk in Patients Treated with Non-Anti-Tumor Necrosis Factor-α (TNF-α) Targeted Biologics and Recently Licensed TNF-α Inhibitors: Data from Clinical Trials and National Registries
Fabrizio Cantini, Laura Niccoli and Delia Goletti

The Journal of Rheumatology Supplement May 1 2014, 91 56-64; DOI: https://doi.org/10.3899/jrheum.140103
Open Access
Vaccine Responses in Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol: Results from a Single-blind Randomized Phase IV Trial
Alan J. Kivitz, Joy Schechtman, Michele Texter, Andreas Fichtner, Marc de Longueville and Elliot K. Chartash

The Journal of Rheumatology April 1 2014, 41 (4) 648-657; DOI: https://doi.org/10.3899/jrheum.130945

Main menu